Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Brain spectroscopy reveals that N-acetylaspartate is associated to peripheral sensorimotor neuropathy in type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mortality and complications after treatment of acute diabetic Charcot foot

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  • Glenn M Chertow
  • Gerald B Appel
  • Geoffrey A Block
  • Melanie P Chin
  • Daniel W Coyne
  • Angie Goldsberry
  • Kamyar Kalantar-Zadeh
  • Colin J Meyer
  • Mark E Molitch
  • Pablo E Pergola
  • Philip Raskin
  • Arnold L Silva
  • Bruce Spinowitz
  • Stuart M Sprague
  • Peter Rossing
Vis graf over relationer

AIMS: Obesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.

METHODS: Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to <30 mL/min/1.73 m2) were randomized 1:1 to receive once-daily oral dose of bardoxolone methyl (20 mg) or placebo.

RESULTS: BEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7 kg; 95% CI: -6.0 to -5.3 kg; p < 0.001). In patients randomized to bardoxolone methyl, rate and magnitude of body weight loss were proportional to baseline BMI. Bardoxolone methyl resulted in significant reductions in waist circumference and improved glycemic control.

CONCLUSIONS: Bardoxolone methyl resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI.

OriginalsprogEngelsk
TidsskriftJournal of Diabetes and its Complications
Vol/bind32
Udgave nummer12
Sider (fra-til)1113-1117
Antal sider5
ISSN1056-8727
DOI
StatusUdgivet - 1 dec. 2018

ID: 55457135